 CAMBRIDGE, Mass.--BUSINESS WIRE--Acceleron Pharma Inc. Nasdaq:XLRN, a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL luspatercept-aamt as reported by its global collaborator, Bristol Myers Squibb, were approximately 115 million for the fourth quarter and approximately 274 million for the full year ended December 31, 2020. Acceleron exp 